ALCO vs PTNM
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
ALCO's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 2/9 indicates poor operational and financial health, with negative margins, losses across all profitability metrics, and a staggering -88.8% revenue decline. The absence of an Altman Z-Score raises red flags for potential bankruptcy risk, while the Graham Number and intrinsic value are unavailable, suggesting no reliable fundamental valuation anchor. Despite a modest dividend yield and a 'strong_buy' analyst consensus, the company's persistent losses, negative cash flows, and deteriorating earnings trends undermine any positive sentiment. The technical trend is bearish, and insider activity is neutral, offering no conviction signal.
PTNM exhibits a critical disconnect between its market price ($10.39) and its fundamental value, with a Piotroski F-Score of 4/9 indicating only mediocre stability. The Graham Number ($0.38) and Intrinsic Value ($0.21) suggest the stock is trading at a massive premium despite negative profit margins (-31.94%) and declining revenue growth (-23.90%). While the balance sheet shows decent liquidity and low leverage, the astronomical P/E (346.33) and Price/Book (48.36) ratios are unsustainable. The company is currently operating as a speculative vehicle rather than a value-driven investment.
Compare Another Pair
Related Comparisons
ALCO vs PTNM: Head-to-Head Comparison
This page compares Alico, Inc. (ALCO) and Pitanium Limited (PTNM) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.